Evidence map›Paper›PMID 42568581›Full record

ArticleFrontiers in immunology2026

Structural quality-tier assessment for TCR-pMHC functional enrichment.

Alex Ascunce-París, Miguel Romero-Durana, Alfonso Valencia, Roc Farriol-Duran, Víctor Guallar

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alex Ascunce-ParísBarcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), Plaça d'Eusebi Güell, Barcelona, Spain.
Miguel Romero-DuranaBarcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), Plaça d'Eusebi Güell, Barcelona, Spain.
Alfonso ValenciaBarcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), Plaça d'Eusebi Güell, Barcelona, Spain.
Roc Farriol-DuranBarcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), Plaça d'Eusebi Güell, Barcelona, Spain.
Víctor GuallarBarcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), Plaça d'Eusebi Güell, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell receptor (TCR) recognition of peptide-MHC complexes (pMHCs) is central to adaptive immunity. Structural insights into TCR-pMHC interactions are critical for understanding antigen specificity and T-cell function. However, progress remains limited by the scarcity of experimentally resolved structures (275 TCR-pMHC class I structures in the PDB, Jan 2026). Although protein structure modelling tools have advanced rapidly, accurate structural modelling of TCRs remains challenging due to CDR loop hypervariability and conformational flexibility. In addition, there is a lack of reliable quality assessment strategies that do not rely on comparisons with experimental references. To address this, we benchmarked four general-purpose (AlphaFold2.3-Multimer, AlphaFold3, Boltz-2, Chai-1) and three TCR-specific (TCRmodel2, tFold-TCR, TCRdock) protein modelling algorithms by recalculating all experimentally determined TCR-pMHC class I complexes in the PDB. AlphaFold3 demonstrated superior performance across metrics (mean TCR-iRMSD = 3.59 Å and DockQ = 0.54), whereas the other algorithms displayed lower accuracy. Built on AlphaFold3 structures, we present a scalable and interpretable ML framework for the quality assessment of TCR-pMHC structural models without matched experimental references. We trained a random forest classifier integrating multiple confidence metrics (pLDDT, ipTM, ipSAE, iPAE, iPDE, pDockQv1-2) derived from 1325 modelled structures of 265 experimentally determined PDB TCR-pMHC class I complexes. The classifier reliably stratifies structural models into low-, acceptable-, medium-, and high-quality tiers defined by comparisons to their experimental reference structures, outperforming single metrics. These quality-tier predictions further enable the prioritization of high-confidence TCR-pMHC interactions. This was demonstrated across two held-out datasets comprising a total of 4,090 AlphaFold3-modelled TCR-pMHC complexes (20,450 models, 5 models per complex): a re-evaluated set of TCR-pMHC class I complexes from VDJdb (n = 606) and the reference IMMREP23 dataset (n = 3,484). We profiled the first dataset to reduce false-positive TCR-pMHC interactions erroneously annotated in VDJdb, and the second to enrich for biologically validated TCR-pMHC interactions amongst higher-quality structural models over their synthetic negative counterparts. Altogether, our structural quality-tier framework provides a scalable and interpretable approach that complements structural modelling and functional analyses of TCR-pMHC class I complexes, with direct translational applications in T-cell immunology and TCR-based immunotherapies.

Indexed as

PeptidesReceptors, Antigen, T-CellAlgorithmsAnimalsDatabases, ProteinHumansImmunoinformaticsModels, MolecularProtein BindingProtein ConformationPeptidesReceptors, Antigen, T-CellAlphaFold3protein modellingstructural quality assessmentT-cell immunotherapiesT cell receptorTCR-pMHC specificity

Identifiers

PMID42568581
PMCPMC13447355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.